---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-23-000119"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:57:56.664274+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Autolus obe-cel FELIX pooled analysis: 78% CR/CRi, 12-mo EFS 50%, low immunotoxicity; BLA filed for r/r B-ALL

## Summary
- Pooled FELIX Phase Ib/II (n=127): CR/CRi rate 78%; grade ≥3 CRS 2%, ICANS 7%; median follow-up 16.6 months.
- Patients with <5% BM blasts at lymphodepletion: 12-mo EFS 65%, no grade ≥3 CRS or ICANS (n=36).
- Pooled ALLCAR19/FELIX Ib (n=36) in r/r B-ALL: 81% remission rate; 41% in ongoing CR at median >3 years follow-up without transplant.
- AUTO8 (BCMA/CD19 dual CAR) MCARTY Phase I (n=11): 100% ORR, 7 CR/sCR, no grade ≥3 CRS/ICANS; trial enrolling.
- BLA for obe-cel in relapsed/refractory adult B-ALL submitted to FDA; ASH data support regulatory filing.

## SEC filing metadata
- accession: 0001730463-23-000119
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000119/0001730463-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000119/autl-20231209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-23-000119
- JSON: https://secwatch.observer/filing/0001730463-23-000119.json
- Plain text: https://secwatch.observer/filing/0001730463-23-000119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.